Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer | MicrobiomeTrials
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-05-27Est. Completion: 2027-11-24
Enrollment target: 44 participants
Locations
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
Los Angeles General Medical Center, Los Angeles, California, United States
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
Emory University Hospital Midtown, Atlanta, Georgia, United States
Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States
University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio, United States
University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, United States
Oregon Health and Science University, Portland, Oregon, United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
VCU Massey Comprehensive Cancer Center, Richmond, Virginia, United States
Other microbiome trials you might be interested in